제약 시장 연구

건강과 웰빙은 삶의 중요한 부분입니다.  

These sectors relate to the development, manufacture, and marketing of medicines.  The global revenue of the pharmaceutical industry is more than $1 trillion. Almost half of this figure comes from two countries: the US and Canada. It is by far the most profitable industry of all. The primary and generic pharmaceutical companies lead the way in the industry.

업계의 일부 혁신은 전문 제약회사에서 나옵니다. 이들 회사 중 일부는 대기업의 단일 부서보다 직원 수가 적습니다. 이러한 소규모 시설은 환자에게 엄청난 영향을 미치고 있습니다. 그들은 치료 분야와 틈새 시장에 집중합니다. 이들 회사는 표적화된 접근 방식이 어떻게 결과를 얻을 수 있는지 보여주고 있습니다. 일부 회사는 한 가지 질병에만 전적으로 집중합니다. 다른 사람들은 인구의 소수에게만 영향을 미치는 질병을 치료합니다.

The US pharmaceutical market dominates the rest of the world. The US is an innovator and a booster in the field of medical research and development. Their R&D benefits the international pharmaceutical industry. Still, one of the top conditions affecting US patients is diabetes. Oncology and autoimmune diseases are also the focus of much research in the US. Pfizer, Johnson & Johnson, and Merck & Co. are the largest companies on the US market.

Pharmaceutical Market Research: How Leading Manufacturers Convert Evidence Into Launch Advantage

Pharmaceutical market research has moved from a launch checkpoint to a continuous decision system that shapes pipeline economics. The teams pulling ahead treat evidence generation as a portfolio asset, not a study line item. They sequence indications, refine payer value stories, and adjust KOL mapping based on signals collected long before phase three readouts.

The upside is concrete. Manufacturers who tie real-world evidence and competitive intelligence into a single decision cadence compress launch sequencing, defend price, and capture formulary positions earlier. The discipline rewards specificity. Generic insights produce generic launches.

What Pharmaceutical Market Research Looks Like When It Drives Decisions

The conventional model treats research as discrete deliverables: an HTA submission evidence dossier here, a payer interview round there, a tracker every quarter. The better model treats these as inputs into a single launch readiness signal that updates monthly.

Three inputs do the heaviest lifting. First, structured KOL mapping that identifies prescribing influence by therapeutic node, not title. Second, payer value story testing against real reimbursement archetypes in the US, Germany, France, the UK, and Japan. Third, competitive intelligence on rival manufacturing, trial design, and indication strategy. Roche, Novartis, and Takeda run versions of this integration. The differentiator is not the inputs. It is the cadence and the willingness to revise launch sequencing on what the evidence shows.

According to SIS International Research, pharmaceutical clients who refresh competitive intelligence on rival manufacturing footprints quarterly, rather than at submission milestones, identify capacity constraints and supply vulnerabilities six to nine months earlier than peers relying on annual scans. That window is often the difference between a defensive launch and a category-defining one.

Why Indication Prioritization Is Where the Value Compounds

Indication prioritization is the most underweighted decision in pharmaceutical market research. Most teams optimize for the largest addressable population. The leaders optimize for the indication where payer value story, KOL receptivity, and competitive whitespace align.

This requires evidence that crosses functions. A strong oncology asset may have a larger second-line opportunity but a faster path to formulary positioning in a niche first-line subpopulation where biosimilar competitive intelligence shows incumbents retreating. The market research function that catches this earns its budget for the decade.

Pfizer’s sequencing of Ibrance across metastatic breast cancer subtypes and Vertex’s expansion logic in cystic fibrosis both reflect this discipline. The shared pattern is patience on volume in exchange for clean payer narratives and durable KOL endorsement.

The Payer Value Story Has Become the Asset

HTA submission evidence requirements in the UK, Germany, and France have tightened around comparative effectiveness and budget impact. The manufacturers winning access build the payer value story two years before submission and stress test it through structured payer interviews in each archetype market.

The mechanism matters. NICE, G-BA, and HAS each weight evidence differently. G-BA’s added benefit assessment penalizes weak comparator selection. NICE’s ICER thresholds reward credible real-world evidence. HAS values transparency on subpopulation effect. A single global value story translated late into local dossiers loses ground in all three.

SIS International’s structured expert interviews with senior payers and HTA assessors across European and Asia-Pacific markets indicate that manufacturers who pre-test value story logic with former assessors twelve to eighteen months before submission achieve materially stronger first-cycle reimbursement decisions than those who validate only through advisory boards.

Competitive Intelligence Beyond the Pipeline Tracker

Most competitive intelligence in pharma stops at the pipeline tracker. The work that actually changes decisions goes deeper into manufacturing footprint, API sourcing, trial site selection, and KOL contracting patterns.

Site investigation in China and India for competitive API and finished dose facilities reveals capacity decisions that pipeline databases miss by twelve to twenty-four months. Trial site overlap analysis exposes recruitment competition that affects enrollment timelines. KOL contracting patterns signal which competitors are positioning for specific indications.

SIS International has conducted facility-level competitive intelligence on drug manufacturing sites in China, including pain management category investigations where understanding a competitor’s installed tabletting capacity, idle capacity, and pharmacopeia compliance (USP, BP, IP, EP) shifted a client’s launch timing by two quarters. This is the level of specificity that separates intelligence from news.

Real-World Evidence Is Becoming the Second Trial

Real-world evidence has moved from post-launch nice-to-have to pre-launch essential. The FDA, EMA, and PMDA increasingly accept RWE in label expansions, reimbursement, and safety signal management. Manufacturers building RWE infrastructure during phase two, not after approval, accelerate label expansion and defend formulary positioning against biosimilars.

The mechanism is sequencing. RWE generation in oncology, rare disease, and cardiometabolic categories now drives indication prioritization decisions because payers and HTA bodies treat strong RWE as comparable to additional trial arms in specific contexts. Bristol Myers Squibb and AstraZeneca have visibly built this capability into their evidence planning.

The SIS Pharmaceutical Evidence Stack

A useful frame for organizing pharmaceutical market research:

Source: SIS International Research

Where Pharmaceutical Market Research Is Heading

Three shifts are reshaping the function. Decentralized trials are changing patient journey mapping by surfacing real adherence behavior earlier. AI-driven literature and patent analytics are compressing competitive intelligence cycle times from weeks to days, freeing analysts to focus on primary signal collection. And payer consolidation in the US and 유럽 is raising the bar on payer value story specificity, since fewer accounts now control more lives.

The manufacturers gaining ground share one pattern. They treat pharmaceutical market research as a continuous portfolio function tied to launch sequencing, indication prioritization, and formulary positioning, not as a service line that produces decks. The evidence is generated against named decisions. The cadence matches the pace of competitive moves, not the pace of internal calendars.

The upside for VPs running this function is significant. A well-instrumented pharmaceutical market research engine measurably shortens time to peak share, defends price longer, and reduces the cost of failed indications. The teams that build it will spend the next decade selling into more receptive payer environments than the teams that do not.

SIS 인터내셔널 소개

SIS 국제 정량적, 정성적, 전략 연구를 제공합니다. 우리는 의사결정을 위한 데이터, 도구, 전략, 보고서 및 통찰력을 제공합니다. 또한 인터뷰, 설문 조사, 포커스 그룹, 기타 시장 조사 방법 및 접근 방식을 수행합니다. 문의하기 다음 시장 조사 프로젝트를 위해.